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Purpose: To evaluate the intraocular pressure (IOP) reducing effect of a ﬁ  xed combination of 
0.005% latanoprost and 0.5% timolol in patients with an IOP of 30 mmHg or higher.
Design: Prospective, randomized clinical trial.
Participants: Twenty-eight patients.
Methods: Patients had received no prior medical glaucoma treatment. Routine ophthalmic exam-
inations and visual ﬁ  eld tests were performed before and after treatment for each patient.
Results: Mean IOP was 32.28 ± 0.92 mmHg before treatment. Mean IOP levels were 
18.75 ± 0.68 for the ﬁ  rst day, 17.96 ± 0.90 for the ﬁ  rst week and 17.64 ± 0.66 for the ﬁ  rst 
month after treatment.
Conclusion: A ﬁ  xed combination of latanoprost 0.005% and timolol 0.5% is effective in 
signiﬁ  cantly reducing IOP in glaucoma patients with an IOP greater than 30 mmHg.
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Introduction
Glaucoma needs to be treated in order to prevent development of additional impairment 
in the optic disc in the long term and to maintain the intraocular pressure (IOP) level to 
restrict any potential loss in the visual ﬁ  eld or visual acuity.1 IOP is a correctable factor 
in glaucoma, and a reduction in IOP can typically be achieved by medication, laser 
treatment or surgery. The standard approach for medication is to initiate a monotherapy 
with an individual agent.2 The prostaglandin analogues, the most common medica-
tions indicated, can reduce IOP by up to 30%. Particularly when used in combination, 
instilling a drop immediately after the ﬁ  rst drop of the other agent will result in both 
removal of the ﬁ  rst agent from the ﬁ  eld and reduced concentration of the second agent. 
Studies have shown that administration of more than two drops daily directly reduces 
patient compliance. Fixed combinations of glaucoma medications reduce the number 
of bottles of medication patients need to purchase, which can represent a cost saving 
for those whose drug plan requires a per bottle copayment.3 Fixed combinations also 
represent a reduction in the number of drops per day required to be instilled.3
In this study we evaluated the efﬁ  cacy of a ﬁ  xed combination of 0.005% latanoprost 
and 0.5% timolol in lowering the IOP as a ﬁ  rst-line therapy in glaucoma patients with 
an IOP greater than 30 mmHg.
Materials and methods
The study included a total of 28 patients (15 females, 13 males), who had been ini-
tially diagnosed with glaucoma in the Glaucoma Unit of the Eye Clinic of the Fatih 
Sultan Mehmet Training and Research Hospital. Mean age was 58.64 ± 8.84 years. 
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glaucoma were eligible for the study as well as those who 
had no prior glaucoma treatment, and an IOP higher than 
30 mmHg at two measurements within the same day. Pre- 
and post-treatment measurements for visual acuity, anterior 
segment and fundus examination, IOP by Goldmann appla-
nation tonometry, visual ﬁ  eld testing (Humphrey 30–2 full 
threshold) and central corneal thickness were performed for 
each patient. The IOP measurements were obtained at 8 AM 
and 4 PM. At each time point, two measurements were taken 
to provide the mean IOP value. Patients with a contraindica-
tion for latanoprost and timolol therapy, a history of angle 
closure glaucoma, uveitis, surgery or any topical or systemic 
nonsteroidal anti-inﬂ  ammatory drug and steroid use were 
excluded from the study. One drop of the latanoprost–timolol 
ﬁ  xed combination was applied at 9 PM. The pre- and post-
treatment IOP values at day 1, week 1 and month 1 were 
compared statistically using the Wilcoxon signed-rank test.
Results
Of the eyes included in the study, 21 had primary open angle 
glaucoma, 6 had pseudoexfoliative glaucoma, and 1 pigmentary 
glaucoma. Patient demographic characteristics are shown in 
Table 1. Treatment was discontinued in 1 patient due to lack 
of efﬁ  cacy. IOP was diminished only 5% in this patient and 
was not included in the analyses. The mean pre-treatment 
IOP was 32.28 ± 0.92 mmHg. Following treatment, 
mean IOP values were: 18.75 ± 0.68 mmHg (p  0.05) 
at day 1; 17.96 ± 0.90 mmHg (p  0.05) at week 1; and 
17.64 ± 0.66 mmHg (p  0.05) at month 1 (Table 2). 
The reduction in the IOP was –13.53 ± 0.24 mmHg, 
14.32 ± 0.02 mmHG, and 14.64 ± 0.26 mmHg at day 1, 
week 1 and month 1, respectively. A statistically signiﬁ  cant 
difference in IOP values compared to the pre-treatment 
period was observed for all intervals. The side effects 
included burning and stinging in 1 patient, redness in 
1 patient, and itching in 1 patient.
Discussion
Higher concentrations of prostaglandins (PG) may elevate 
IOP, resulting in inﬂ  ammation of the eye, whereas lower 
concentrations may reduce IOP by increasing the uveoscleral 
outﬂ  ow. Latanoprost, released commercially several years 
ago, is an analogue of an F2α prostaglandin and is highly 
selective for the FP receptor.4 PGs bind to the receptors 
on the ciliary muscles, affecting the uveoscleral outﬂ  ow. 
By increasing the outﬂ  ow of the aqueous humor through 
the uveoscleral pathway, latanoprost has an additive effect 
with agents that elevate the trabecular ﬂ  ow and decrease 
the aqueous production. It is used once daily.4 IOP can be 
signiﬁ  cantly reduced when latanaprost is added to the regi-
men in patients with open angle glaucoma which could not 
be controlled by timolol.
Beta-blockers or prostaglandins are used in the ﬁ  rst-line 
therapy for many glaucoma patients. In cases where a more 
effective therapy is required, ﬁ  xed combination drops with 
two active agents should be preferred instead of a second 
agent. Previous studies have shown that the latanoprost–
timolol ﬁ  xed combination therapy is more effective than 
the monotherapies alone.5 Shin et al showed, similar to our 
study, that the latanoprost–timolol ﬁ  xed combination is an 
effective and safe treatment option in reducing IOP.6 We 
found that the latanoprost–timolol ﬁ  xed combination used as 
a ﬁ  rst-line therapy reduced IOP by approximately 43% within 
a short period of time. Furthermore, it has been reported that 
Table 1 Demographic characteristics of patients
Type of glaucoma Primary open angle 
glaucoma
Pseudoexfoliative 
glaucoma
Pigmentary 
glaucoma
Female 15 (53.57%) 10 (35.71%) 4 (14.28%) 1 (3.57%)
Male 13 (46.42%) 11 (39.28%) 2 (7.14%)
Total 28 21 (75%) 6 (21.42%) 1 (3.57%)
Table 2 Pre-treatment and post-treatment intraocular pressure (IOP) values
Pre-treatment 
IOP (mean 
mmHg ± SD)
Post-treatment 
IOP Day 1 
(mean 
mmHg ± SD)
Post-treatment 
IOP week 1 
(mean 
mmHg ± SD)
Post-treatment 
IOP Month 1 
(mean 
mmHg ± SD)
Post-treatment 
IOP Month 6 
(mean 
mmHg ± SD)
Pre-treatment 
visual ﬁ  eld mean 
deviation (dB)
Post-treatment 
IOP mean 
deviation (dB)
32.28 ± 0.92 18.75 ± 0.68 
(p  0.05)
17.96 ± 0.90 
(p  0.05)
17.64 ± 0.66 
(p  0.05)
17.46 ± 0.50 
(p  0.05)
–3.1 ± 3.9 –3.3 ± 4.1 
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the mean reduction obtained by a latanoprost-based ﬁ  xed 
combination was 1.0 mmHg higher compared with a dorzol-
amide-based ﬁ  xed combination twice a day, along a diurnal 
curve with three timepoints.6 It has been demonstrated that 
the latanoprost–timolol ﬁ  xed combination therapy decreasess 
IOP by more than 2.9 mmHg compared with timolol alone, 
and by more than 1.1 mmHg compared with latanoprost 
alone.7 Although diverse rates of iris pigmentation have been 
reported in previous studies,8,9 we believe that lack of any 
iris pigmentation in our cases might have been associated 
with the shorter study period.
We believe that our study group was preliminary, 
consisting of a limited number of patients, and patient adher-
ence to the therapy was closely related to once-daily dosage. 
In conclusion, our short study has shown that the 0.005% 
latanoprost and 0.5% timolol ﬁ  xed combination is effective 
in signiﬁ  cantly reducing IOP in glaucoma patients with an 
IOP greater than 30 mmHg.
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